Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab and Erlotinib in Advanced NSCLC
NCT00778167Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2008
- Primary completion
- May 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cixutumumab in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Oct 2008; status: completed.
02
Drugs
cixutumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00778167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00778167.